Dr. Dariush Mozaffarian, a cardiologist and director of the Food is Medicine Institute at Tufts University, said a healthy diet could help “most individuals” with Type 2 diabetes lower their blood ...

New research suggests the risks tied to early pregnancy exposure to popular weight loss drugs may not be the same for every patient.

GLP-1 receptor agonist use in adults with concurrent type 2 diabetes and obesity was associated with increased risk for osteoporosis, gout and osteomalacia vs. a matched control group, according to ...

Greater lifetime exposure to blood sugar highs and lows may raise the risk of vascular damage and cognitive decline for people with type 1 diabetes.

A new real-world analysis suggests that cardio-kidney-metabolic (CKM) therapies, widely used in type 2 diabetes (T2D), may offer meaningful kidney benefits for patients with type 1 diabetes (T1D) and ...

Stopping GLP-1 medications is linked to a higher risk of heart attack, stroke, and death. Recent research found that even ...

In a new GLP-1 study, semaglutide appeared to reduce the incidence of mental-health sick days and hospitalization, suggesting improved mood.

Right now, the drugs come with a hefty price tag. Ozempic typically runs 8,800 to 11,000 rupees ($95–$119) per month, while Wegovy can cost 10,000 to 16,000 rupees ($108–$173), depending on the dose.

GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.

A new class of weight loss drug just took a major step toward approval for use. In a phase III clinical trial, medication ...

A new KFF survey shows many Americans who had Affordable Care Act marketplace health insurance last year are struggling with ...

W hen first diagnosed with type 2 diabetes, you may have been able to manage blood sugar levels with diet, exercise, and a first-line medication. But as the condition progresses, the body becomes more ...